Camlipixant

DB19217InvestigationalSmall molecule

Camlipixant is under investigation in clinical trial NCT05600777 (A 24-week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)).

Mechanism: Pharmacologically active on P2X purinoceptor 3
Curator reviewed
Formula / weight: C₂₃H₂₄F₂N₄O₄ · 458.466 g/mol (avg)
Also known as: 4-morpholinecarboxylic acid, 2-((2-(2,6-difluoro-4-((methylamino)carbonyl)phenyl)-7-methylimidazo(1,2-a)pyridin-3-yl)methyl)-, methyl ester, (2s)-
Code names: AZ-13410937 · BLU-5937 · NEO-5937

Resolves to

Compound

UNIITB7D2H7MZZCAS1621164-74-6ChEMBLCHEMBL5095035

Structure

InChIKeySEHLMRJSQFAPCJ-HNNXBMFYSA-NSMILESCNC(=O)C1=CC(F)=C(C2=C(C[C@H]3CN(CCO3)C(=O)OC)N3C=CC(C)=CC3=N2)C(F)=C1

Targets

P56373P2RX3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Camlipixant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account